The reduction in price target by Barclays may have a neutral to slightly negative short term impact on Jazz Pharmaceuticals' stock price as it suggests a lower valuation than previously estimated. However, the Overweight rating indicates that the analyst still sees the company as a good investment, which could mitigate any negative reaction.